the ESSENTIAL issue neleafmag.COM
34
CBN& sLEEP CURIO WELLNESS’ INNOVATIONS
THE CONCEPT of cannabinoid therapy continues to be one of the most invigorating and promising new frontiers on the legalized Cannabis landscape. The Cannabis plant has roughly 426 chemical entities (and more than 60 cannabinoid compounds) according to the National Institute for Health, and researchers have come to find that many of those compounds react in specific, powerful ways with our bodies’ endocannabinoid system. Many of those cannabinoids have well-known and researched effects. THC provides psychoactive effects, but also helps with gastrointestinal issues, muscle relaxation and other ailments. CBD reduces inflammation and battles anxiety.
Curio Wellness’ Good Night Tablets
FEB. 2021
A large portion of the sleep-affected community has tremendous difficulty staying asleep and gaining the benefit of a full night’s rest. But THC and CBD are a small piece of the puzzle, and as research expands, scientists will further unlock the potential of the wealth of compounds in the Cannabis plant. In short, we’re going to start seeing more effect-based products hitting the market. Curio Wellness, out of Maryland, sees the potential. The company recently released a new product, dubbed Good Night Pulse Release Tablets, in order to help with a specific issue that impacts us all: sleep. In order to help people achieve and maintain a good night’s sleep, Curio Wellness’ Good Night Tablets combine THC with CBN, a lesser-known soporific cannabinoid that in recent years has gained popularity because of its focused sleep-inducing properties. To create a product that consumers could trust, Curio Wellness partnered with SleepScore Labs to conduct an observational sleep study with 35 certified Maryland medical Cannabis patients with self-described sleep disorders, clinically testing their new Good Night Tablets. Their formulation is a 2:1 THC:CBN ratio with each tablet containing 10mg THC and 5mg CBN. Participants completed a six-week comparative study, where for the first three weeks their sleep was monitored in accordance with their existing sleep routine, including any sleep aids they already used. In the second three weeks, patients replaced their routine with use of Good Night Tablets according to the independent study protocol. Across all phases of the study, participants sleep was monitored via the SleepScore Max Device and the completion of self surveys via the SleepScore research app. Participants were also required to stop using any other Cannabis product within three hours of bedtime, to avoid clouding the data while trialing the Good Night product.
The results were successful – according to Curio Wellness, the study showed that when taking the Good Night Tablets, patients showed marked improvement in their objective sleep metrics, as well as participant’s subjective feedback indicating improvement in overall sleep quality. The fact that the study subjects were able to stay asleep through the night is something that Curio Wellness sees as a significant factor. A large portion of the sleep-affected community has tremendous difficulty staying asleep and gaining the benefit of a full night’s rest. Falling asleep may be difficult, but staying asleep is what prevents many people from reaching REM sleep and achieving a well-rested body. Curio’s Pulse Release Technology, which allows for targeted dosages at targeted times to interact with the patient’s system, ensures that several hours after ingestion, a second wave of effects enters the body to help keep the patient asleep. This means that by taking one dose, patients feel the initial drowsy effects to help enter a state of sleep, as well as a second targeted release of the cannabinoids several hours after ingestion to help you stay asleep – greatly increasing the probability of a patient sleeping through the entire night. Curio Wellness’ approach to clinical research and product development is refreshing in an industry where many companies simply seek to market products based on trends, not on what they can actually provide to patients and consumers. Everything with Cannabis is dose-dependent around an individual’s tolerance and tied to how the plant interacts with endocannabinoid systems, and we are at the beginning of the journey to unlock what this plant can do. CURIOWELLNESS.COM | @CURIO_WELLNESS
STORY by TAYLOR MARTIN & LEAF NATION CONTRIBUTORS | ILLUSTRATION by ADOBE/ARTINSPIRING + COURTESY CURIO
